What were the results of the ADVOCATE study on cholesterol-modulating agents for the treatment of low HDL cholesterol (hypoalphalipoproteinemia)?

Updated: May 21, 2021
  • Author: Vibhuti N Singh, MD, MPH, FACC, FSCAI; Chief Editor: George T Griffing, MD  more...
  • Print

In the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation (ADVOCATE), 315 patients with high LDL (≥160 mg/dL without CAD, or ≥130 mg/dL with CAD) and low HDL (< 45 mg/dL in men, and < 50 mg/dL in women) were randomized to 16 weeks of a combination of niacin/lovastatin versus standard doses of atorvastatin or simvastatin. Niacin/lovastatin increased HDL significantly more than did statin alone at all dose combinations (P< 0.001). In addition, a significant decrease in LDL (42% vs 34%; P< 0.001) and significant improvements in TGs, lipoprotein(a), apo A-I, and apo B were seen in those patients receiving niacin/lovastatin (no longer on U.S. market).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!